• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $134 Million Bet On This Stock Up 46% Year-To-Date? 3 Stocks Insiders Are Buying

    11/2/22 8:51:18 AM ET
    $DVA
    $SRLP
    $TBBK
    Misc Health and Biotechnology Services
    Health Care
    Oil Refining/Marketing
    Energy
    Get the next $DVA alert in real time by email

    Although US stocks closed lower on Tuesday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    DaVita

    • The Trade: DaVita Inc. (NYSE:DVA) Director John Nehra acquired a total of 5,000 shares an average price of $71.14. To acquire these shares, it cost around $355.68 thousand.
    • What’s Happening: DaVita recently reported worse-than-expected Q3 results and lowered FY22 adjusted EPS guidance below estimates.
    • What DaVita Does: DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics.

    The Bancorp

    • The Trade: The Bancorp, Inc. (NASDAQ:TBBK) Director Matthew Cohn acquired a total of 20,910 shares at an average price of $28.00. To acquire these shares, it cost around $585.38 thousand.
    • What’s Happening: The company recently posted downbeat quarterly earnings.
    • What The Bancorp Does: The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations.

    Don’t forget to check out our premarket coverage here .

    Also check this: Market Volatility Increases As Investors Await Fed's Rate Decision

    Sprague Resources

    • The Trade: Sprague Resources LP (NYSE:SRLP) 10% owner Hartree Partners GP LLC bought a total of 6,689,383 shares at an average price of $20.00. To acquire these shares, it cost around $133.79 million.
    • What’s Happening: Sprague Resources announced closing of merger with Hartree Affiliate and delisting of its common units.
    • What Sprague Resources Does: Sprague Resources LP engaged in the purchase, storage, distribution and sale of refined products and natural gas, and to provide storage and handling services for a broad range of materials.
    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA
    $SRLP
    $TBBK

    CompanyDatePrice TargetRatingAnalyst
    The Bancorp Inc
    $TBBK
    3/12/2026$66.00Overweight
    Piper Sandler
    The Bancorp Inc
    $TBBK
    8/11/2025$76.00Outperform → Strong Buy
    Raymond James
    The Bancorp Inc
    $TBBK
    6/12/2025$65.00Outperform → Mkt Perform
    Keefe Bruyette
    DaVita Inc.
    $DVA
    3/6/2024$133.00Equal Weight
    Barclays
    DaVita Inc.
    $DVA
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    The Bancorp Inc
    $TBBK
    1/30/2023$38.00Outperform
    Raymond James
    DaVita Inc.
    $DVA
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    DaVita Inc.
    $DVA
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    More analyst ratings

    $DVA
    $SRLP
    $TBBK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 332 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:18 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:04 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $SRLP
    $TBBK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Bancorp, Inc. Sets First Quarter 2026 Financial Results Release Date and Conference Call

    The Bancorp, Inc. ("Bancorp") (NASDAQ:TBBK) today announced that it will release its first quarter 2026 financial results after market hours on Thursday, April 23, 2026, and invites investors and other interested parties to listen to its earnings results conference call on Friday, April 24, 2026, at 8:00 a.m. Eastern time. All interested parties can access the live conference call webcast by visiting The Bancorp site at www.thebancorp.com and clicking on the webcast link located on the home page or by dialing 1.800.715.9871 (conference ID 9545117). The Bancorp's earnings release and updated investor presentation will be available in the Investor Relations section of The Bancorp's website

    4/10/26 8:30:00 AM ET
    $TBBK
    Major Banks
    Finance

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

    AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit

    3/17/26 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $SRLP
    $TBBK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on The Bancorp with a new price target

    Piper Sandler resumed coverage of The Bancorp with a rating of Overweight and set a new price target of $66.00

    3/12/26 8:55:08 AM ET
    $TBBK
    Major Banks
    Finance

    The Bancorp upgraded by Raymond James with a new price target

    Raymond James upgraded The Bancorp from Outperform to Strong Buy and set a new price target of $76.00

    8/11/25 9:34:28 AM ET
    $TBBK
    Major Banks
    Finance

    The Bancorp downgraded by Keefe Bruyette with a new price target

    Keefe Bruyette downgraded The Bancorp from Outperform to Mkt Perform and set a new price target of $65.00

    6/12/25 7:53:00 AM ET
    $TBBK
    Major Banks
    Finance

    $DVA
    $SRLP
    $TBBK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.

    SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)

    3/26/26 5:39:34 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by The Bancorp Inc

    SCHEDULE 13G/A - Bancorp, Inc. (0001295401) (Subject)

    3/26/26 4:11:42 PM ET
    $TBBK
    Major Banks
    Finance

    SEC Form 10-K filed by The Bancorp Inc

    10-K - Bancorp, Inc. (0001295401) (Filer)

    2/25/26 5:18:35 PM ET
    $TBBK
    Major Banks
    Finance

    $DVA
    $SRLP
    $TBBK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Canuso Dominic C bought $110,510 worth of shares (2,000 units at $55.26), increasing direct ownership by 12% to 18,169 units (SEC Form 4)

    4 - Bancorp, Inc. (0001295401) (Issuer)

    3/2/26 4:02:13 PM ET
    $TBBK
    Major Banks
    Finance

    Director Cohn Matthew bought $65,000 worth of shares (1,080 units at $60.18) (SEC Form 4)

    4 - Bancorp, Inc. (0001295401) (Issuer)

    2/12/26 5:09:11 PM ET
    $TBBK
    Major Banks
    Finance

    EVP & Chief Financial Officer Canuso Dominic C bought $182,777 worth of shares (3,000 units at $60.93) and was granted 9,669 shares, increasing direct ownership by 362% to 16,169 units (SEC Form 4)

    4 - Bancorp, Inc. (0001295401) (Issuer)

    2/10/26 6:34:32 PM ET
    $TBBK
    Major Banks
    Finance

    $DVA
    $SRLP
    $TBBK
    Leadership Updates

    Live Leadership Updates

    View All

    The Bancorp Appoints Dominic Canuso as Chief Financial Officer

    The Bancorp, Inc. (NASDAQ:TBBK), today announced the appointment of Dominic C. Canuso as Chief Financial Officer. In this role, Canuso will oversee the company's financial strategy and operations, guiding The Bancorp's continued growth and execution of its long-term strategic initiatives. "Dominic brings a strong record of financial leadership and strategic vision to The Bancorp," said Damian Kozlowski, Chief Executive Officer, The Bancorp. "His experience leading complex organizations through periods of transformation and expansion aligns with our continued focus on growth, innovation, and operational excellence. We are thrilled to welcome Dominic to our executive leadership team." Can

    11/3/25 9:00:00 AM ET
    $TBBK
    Major Banks
    Finance

    The Bancorp Appoints Dwayne Allen to Its Board of Directors

    The Bancorp, Inc. (NASDAQ:TBBK), through its subsidiary, The Bancorp Bank, N.A. (collectively, the "Company" or "The Bancorp"), appointed Dwayne Allen to the Company's Board of Directors, effective January 1, 2025. The addition of Allen will help drive the ongoing growth of The Bancorp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121725354/en/Dwayne Allen Appointed to The Bancorp Board of Directors (Photo: Business Wire) Allen brings more than 25 years of senior leadership experience in technology and digital transformation, spanning a variety of global industries. Since 2021, he has served as Senior Vice President and Chi

    1/21/25 4:06:00 PM ET
    $TBBK
    Major Banks
    Finance

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    $SRLP
    $TBBK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by The Bancorp Inc

    SC 13G - Bancorp, Inc. (0001295401) (Subject)

    10/16/24 12:09:13 PM ET
    $TBBK
    Major Banks
    Finance

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by The Bancorp Inc (Amendment)

    SC 13G/A - Bancorp, Inc. (0001295401) (Subject)

    2/13/24 5:00:45 PM ET
    $TBBK
    Major Banks
    Finance

    $DVA
    $SRLP
    $TBBK
    Financials

    Live finance-specific insights

    View All

    The Bancorp, Inc. Sets First Quarter 2026 Financial Results Release Date and Conference Call

    The Bancorp, Inc. ("Bancorp") (NASDAQ:TBBK) today announced that it will release its first quarter 2026 financial results after market hours on Thursday, April 23, 2026, and invites investors and other interested parties to listen to its earnings results conference call on Friday, April 24, 2026, at 8:00 a.m. Eastern time. All interested parties can access the live conference call webcast by visiting The Bancorp site at www.thebancorp.com and clicking on the webcast link located on the home page or by dialing 1.800.715.9871 (conference ID 9545117). The Bancorp's earnings release and updated investor presentation will be available in the Investor Relations section of The Bancorp's website

    4/10/26 8:30:00 AM ET
    $TBBK
    Major Banks
    Finance

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    The Bancorp Reports 4Q 2025 EPS of $1.28, ROA of 2.53% and ROE of 30.4% Driven by NIM of 4.30%, Continued Fintech Fee Growth, and $150 Million in Share Repurchases in the Quarter

    Fourth Quarter 2025 Highlights Earnings per diluted share ("EPS") of $1.28 compared to $1.15 for 4Q 2024, an increase of 11%. Return on assets of 2.53% compared to 2.60% for 4Q 2024. Return on equity of 30.43% compared to 27.71% for 4Q 2024. Net income of $56.3 million compared to net income of $55.9 million for 4Q 2024. Net interest income of $92.1 million compared to $94.3 million for 4Q 2024. Net interest margin of 4.30% compared to 4.55% for 4Q 2024. Ending Loans, net of deferred fees and costs of $7.12 billion, compared to $6.11 billion at 4Q 2024, or 16% increase, and $6.67 billion at 3Q 2025, or 7% increase (not annualized). Ending Consumer fintech loans of $1

    1/29/26 4:25:00 PM ET
    $TBBK
    Major Banks
    Finance